Neuronetics demonstrates a compelling integrated business model that combines proprietary TMS technology with a scalable clinic network, enabling diversified and recurring revenue streams. The Greenbrook acquisition is transformative, shifting revenue toward higher recurring clinic income and expan…
Neuronetics (STIM) Q1 2025: 84% Revenue Surge Driven by Greenbrook Integration and BMP Expansion
Neuronetics’ first quarter 2025 results reflect the transformative impact of the Greenbrook acquisition, with strong revenue growth and operational progress in mental health treatment delivery. The company’s integrated model combining device sales and clinic operations is driving patient access and financial scale, while strategic initiatives like the Better Me Provider (BMP) program and Spravato rollout accelerate utilization and revenue diversification. The path to cash flow positivity in Q3 is reinforced by synergy realization and expanded insurance coverage.
Summary
- Integrated Growth Model Strength: Greenbrook acquisition and BMP program are expanding patient access and driving revenue diversification.
- Operational Momentum: Spravato rollout and revenue cycle enhancements are improving clinic performance and utilization.
- Financial Discipline: Cost synergies and strategic expense acceleration position Neuronetics for cash flow positive Q3 2025.
Business Overview
Neuronetics is a vertically integrated medical technology and healthcare company specializing in neurohealth therapies, primarily through its NeuroStar Advanced Therapy System, a transcranial magnetic stimulation (TMS) device for treating major depressive disorder (MDD) and related conditions. The company generates revenue from device sales, treatment sessions, and operates a network of clinics via its Greenbrook acquisition, offering a comprehensive mental health treatment platform. Its major segments include device sales, treatment session revenue, and clinic operations, with the latter now a significant contributor following the Greenbrook integration.
Performance Analysis
In Q1 2025, Neuronetics reported total revenue of $32.0 million, marking an 84% increase year-over-year primarily due to the Greenbrook acquisition. On a pro forma basis excluding the acquisition’s prior year contribution, revenue rose 7%, reflecting organic growth within the combined entity. The Greenbrook clinic business contributed $18.7 million, comprising over half of total revenues, underscoring the shift towards integrated care delivery. Device sales (NeuroStar Advanced Therapy System) declined 14% to $2.8 million with 31 systems shipped, though average selling prices improved by 9%. Treatment session revenue fell 26% to $9.6 million, influenced by the elimination of prior Greenbrook session sales and shifts in utilization.
Gross margin compressed to 49.2% from 75.1% in the prior year quarter, driven by the lower-margin clinic operations and the absence of Greenbrook treatment session sales. Operating expenses increased 35% to $26.8 million, mainly due to Greenbrook’s inclusion and deliberate acceleration of certain expenses to secure vendor concessions. Net loss widened to $12.7 million, reflecting investments in growth and integration. Importantly, Neuronetics raised $18.9 million in net proceeds from a February secondary offering, strengthening liquidity and enabling strategic initiatives. Cash used in operations was $17.0 million in Q1, with expectations to reduce cash burn below $5 million in Q2, supporting a targeted cash balance above $20 million by year-end.
- Revenue Mix Shift: Greenbrook clinics now drive the majority of revenue, highlighting a pivot to integrated service delivery.
- Margin Pressure from Integration: Lower clinic margins and session revenue shifts compressed gross margin, a transitional effect of acquisition.
- Expense Management: Accelerated vendor payments and integration costs increased Q1 cash burn but aim to reduce overall 2025 expenses.
The quarter demonstrates the evolving business model from device-centric to a more diversified and scalable platform combining technology and treatment services, positioning Neuronetics for sustainable growth.
Executive Commentary
"Our growth initiatives for the Greenbrook clinics continue to exceed expectations, as we implement our proven operating model and continue to rollout SPRAVATO across our network of locations and institute the buy-and-bill model."
Keith J. Sullivan, President and Chief Executive Officer
"We proactively settled Greenbrook’s legacy vendor payment plans and accelerated certain expenses to secure favorable vendor concessions. While this increased first quarter cash burn, it will reduce overall vendor spending in 2025."
Steve Furlong, Chief Financial Officer
Strategic Positioning
1. Greenbrook Integration and Growth
Neuronetics has successfully integrated Greenbrook’s 95 clinics, leveraging regional account managers and patient coordinators to enhance patient conversion and education. The rollout of Spravato, a nasal spray treatment for depression, expanded to 75 clinics, with 42 implementing the higher-revenue buy-and-bill model, tripling revenue per treatment compared to prior methods. Clinic revenue per site increased 41% year-over-year, supported by operational standardization and revenue cycle management improvements, positioning Greenbrook as a growth engine.
2. Better Me Provider (BMP) Program Expansion
The BMP program, which certifies clinics meeting patient responsiveness and educational standards, grew to over 385 active sites with 110 more working towards certification. BMP sites treat three times more patients per quarter than non-BMP sites and reduce patient wait times by half. The program’s success is supported by targeted marketing efforts and physician network education, strengthening patient access and utilization of NeuroStar TMS.
3. Diversification of Treatment Modalities
Beyond TMS, Neuronetics is advancing Spravato adoption within its clinic network, which grew 50% year-over-year. This diversification broadens the therapeutic offering, addresses unmet clinical needs, and enhances revenue streams. The company’s focus on adolescent treatment, FDA-cleared in 2024, taps into a large underserved population, supported by expanding insurance coverage from major payors, bolstering long-term growth prospects.
4. Cost Synergies and Operational Efficiency
Realized cost synergies from the Greenbrook acquisition exceeded initial expectations, reaching 95% of $22.5 million annualized synergies by year-end 2024, with potential to surpass $23 million. The company continues to identify additional efficiencies, balancing integration costs with ongoing expense discipline. Accelerated vendor payments and software system upgrades aim to improve cash flow and operational scalability.
5. Strengthened Financial Position and Path to Profitability
The successful secondary offering in February fortified the balance sheet, providing capital to accelerate growth initiatives without altering the timeline to cash flow positive in Q3 2025. Management’s focus on revenue growth, cost control, and operational improvements supports this milestone, with guidance indicating narrowing revenue ranges and stable gross margin expectations despite integration-related pressures.
Key Considerations
Neuronetics’ first quarter reflects a strategic inflection point as it transitions from a device-centric model to an integrated mental health care platform. Key considerations for investors include:
- Revenue Quality Shift: The growing dominance of clinic revenue introduces margin variability but offers scalability and recurring revenue potential.
- Integration Execution: Continued operational harmonization of Greenbrook is critical to sustaining growth and realizing cost synergies.
- Adolescent Market Opportunity: FDA clearance and expanding insurance coverage position adolescent treatment as a meaningful growth driver.
- Cash Flow Management: Expense acceleration in Q1 is a deliberate trade-off to improve vendor relations and reduce future cash outflows.
- Market Education and Referral Networks: Efforts to engage primary care providers through the NeuroStar Connection Network are essential to expanding patient access.
Risks
Risks include the potential for slower-than-expected integration of Greenbrook operations, challenges in sustaining cost synergies, variability in insurance reimbursement policies, and competitive pressures from alternative mental health therapies. Additionally, operational execution of the Spravato rollout and BMP program expansion must maintain momentum to meet growth expectations. Macro factors such as tariff impacts on component sourcing remain manageable but require monitoring.
Forward Outlook
For Q2 2025, Neuronetics guides revenue between $36.0 million and $38.0 million, reflecting continued growth in clinic operations and treatment utilization. Full-year 2025 revenue guidance is narrowed to $149.0 million to $155.0 million, up from the prior lower bound, with gross margin expected near 55%. Operating expenses are forecasted between $90.0 million and $98.0 million. Management anticipates operational cash usage below $5 million in Q2 and maintains the target to achieve positive cash flow in Q3 2025.
- Revenue growth driven by Greenbrook utilization and Spravato expansion.
- Ongoing operational improvements and cost synergy realization to support margin expansion.
Takeaways
Neuronetics’ Q1 2025 results highlight the company’s successful transition to an integrated neurohealth platform, leveraging the Greenbrook acquisition and BMP program to drive patient access and revenue growth.
- Integrated Model Validation: The combination of device sales and clinic operations is delivering diversified revenue streams and expanding treatment reach.
- Execution Strength: Operational improvements, including revenue cycle management and standardized training, are enhancing clinic productivity and patient conversion.
- Growth Drivers to Watch: The Spravato buy-and-bill rollout, adolescent treatment adoption, and primary care referral network expansion will be critical to sustaining momentum.
Conclusion
Neuronetics’ first quarter performance demonstrates the strategic benefits of its integrated business model, with robust revenue growth and advancing operational initiatives setting the stage for profitability in Q3 2025. Investors should monitor execution on clinic integration, treatment adoption, and cost management as key indicators of future success.
Industry Read-Through
Neuronetics’ results underscore a broader industry trend towards integrated care delivery models combining medical devices with direct patient services to improve access and outcomes in mental health. The successful expansion of treatment indications and insurance coverage for innovative therapies like TMS and Spravato highlights growing acceptance and reimbursement support. Other players in neurotechnology and mental health services may look to similar integration strategies to drive scale and diversify revenue. Additionally, the focus on adolescent mental health treatment reflects increasing recognition of unmet needs in this demographic, signaling a potential growth area across the sector.